$AIFF moved on the announced expansion of an FDA-cleared ADHD treatment through a new partnership. Its own prior gap-up sessions of 5 percent or more closed above the open in 8 of 14 cases.
The license broadens reach on paper, yet the actual revenue ramp stays outside the current filing.